相关实验视频
Updated: Feb 28, 2026
05:44
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
Published on: June 10, 2025
1.3K
皮肤和粘膜与使用莱夫卢诺米德相关,在三只狗的皮肤和粘膜
Louis F Roussille1, Elizabeth Parsley1, Claire L Fellman1
1Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, United States.
Journal of veterinary internal medicine
|February 26, 2026
概括
勒弗卢诺米德可以导致口腔和皮肤以及狗的肝损伤,这是一种罕见的药物不良反应 (ADR). 这些症状在停止服用药物后消失,这表明与莱夫卢诺米德治疗的潜在联系.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 勒弗卢诺米德用于人类和狗的免疫介导疾病.
- 在人类中已知药物不良反应 (ADR),如口腔/皮肤和药物诱导的肝损伤 (DILI).
- 在狗中报告了leflunomide的肝毒性,但没有描述.
研究的目的:
- 报告一系列狗狗中因莱弗卢诺米德引起的口腔和皮肤的病例.
- 在狗患者中记录并发的 leflunomide 诱导的肝损伤.
- 为了评估这些不良事件的因果关系,使用Naranjo尺度.
主要方法:
- 涉及三只狗的案例系列,这些狗在免疫媒介疾病中接受了 leflunomide 治疗.
- 临床评估 (口腔,皮肤) 和肝损伤.
- 组织学检查受影响的组织.
- 使用Naranjo ADR概率尺度进行因果关系评估.
主要成果:
- 这三只狗都出现了深层口腔和/或皮肤性病变.
- 一只狗同时经历了严重的药物诱导性肝损伤 (DILI).
- 纳兰霍尺度表明可能或可能的标志归因于莱夫卢诺米德.
- 在几周内消失,肝损伤在药物停用后的几个月内消失.
结论:
- 口腔和皮肤是狗中对莱夫卢诺米德的潜在不良药物反应 (ADR).
- 勒弗卢诺米德可以在狗患者中引起显著的肝毒性.
- 停止使用莱夫卢诺米德会导致和肝损伤的消失.
相关概念视频
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
01:29Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.4K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577